Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SIPS-2209 FDC vs Individual Components in Healthy Volunteers
NCT05787873Phase 1Completed
- Sponsor
- Samik Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Samik Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-time curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Started Aug 2022; status: completed.
02
Drugs
sitagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05787873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787873.